

February 11, 2022

To

BSE Limited,

Listing Department, P J Towers,
Dalal Street,
Mumbai – 400 001.

Scrip code: 540679

Through: BSE Listing Center

National Stock Exchange of India Limited,

Listing Department, "Exchange Plaza",
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051.

Trading Symbol: SMSLIFE

Through: NEAPS

SUB: OUTCOME OF THE BOARD MEETING [financial results]

Ref: Regulation 33 read with sub-para 4 of Para "A" of Part "A" of Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

With reference to the above cited subject, we would like to inform you that the Board of Directors of the Company at their Meeting held today i.e. February 11, 2022, have *inter-alia* considered and approved the unaudited [Standalone & Consolidated] Financial results for the quarter and nine-months ended December 31, 2021 along with limited review report, as recommended by the Audit Committee.

In this regard, we are enclosing herewith a copy of the following:

- ✚ Standalone Financial Statements for the quarter and nine-months ended Dec 31, 2021.
- ✚ Consolidated Financial Statements for the quarter and nine-months ended Dec 31, 2021.
- ✚ Limited Review Report for Standalone and Consolidated Financial Statements.

The meeting of the Board commenced at **2.00 pm** and concluded at **3.30 pm**.

For SMS Lifesciences India Limited


Trupii Ranjan Mohanty
Company Secretary



[Enclosed: a/a]

SMS LIFESCIENCES INDIA LIMITED

(CIN: L74930TG2006PLC050223)


Regd. Office: Plot No.19-III, Opp. BVBP School, Road No.71, Jubilee Hills, Hyderabad - 500 096

Tel:+91-40-6628 8888, Fax:91-40-2355 1401, Email: info@smslife.in

Standalone Statement of Un-Audited Financial Results for the Quarter and Nine Months Ended 31st December, 2021

(Rs. In Lakhs)

S.No	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2021	30.09.2021	31.12.2020	31.12.2021	31.12.2020	31.03.2021
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue From Operations	9,268.75	8,475.51	6,543.22	25,066.73	18,073.24	26,025.55
2	Other Income	2.62	71.25	57.36	30.12	41.46	133.28
3	Total Revenue	9,271.37	8,546.76	6,600.58	25,096.85	18,114.70	26,158.83
4	Expenses						
	(a) Cost of Materials Consumed	6,043.33	6,019.87	3,556.75	16,117.43	9,263.66	13,775.91
	(b) Changes in Inventories	(600.33)	(1,088.27)	(138.31)	(1,425.93)	464.53	190.08
	(c) Manufacturing Expenses	1,640.83	1,501.93	1,376.87	4,381.82	3,253.71	4,665.83
	(d) Employee Benefits Expense	885.83	790.41	720.47	2,412.92	1,960.89	2,711.04
	(e) Finance Cost	100.17	131.31	106.13	338.33	352.56	450.02
	(f) Depreciation and Amortization Expense	199.08	206.55	180.40	602.29	539.85	721.33
	(g) Other Expenses	401.10	470.55	284.12	1,149.38	936.43	1,709.18
	Total Expenses - (a to g)	8,670.01	8,032.35	6,086.43	23,576.24	16,771.63	24,223.39
5	Profit Before Exceptional and Extraordinary Items and Tax (3-4)	601.36	514.41	514.15	1,520.61	1,343.07	1,935.44
6	Exceptional / Extraordinary Items	-	777.25	-	777.25	-	-
7	Profit Before Tax (5+6)	601.36	1,291.66	514.15	2,297.86	1,343.07	1,935.44
8	Tax Expenses						
	(1) Current Tax	170.00	308.00	150.00	600.00	400.00	525.00
	(2) Relating to Earlier Year	-	-	-	-	-	(22.31)
	(3) Deferred Tax	1.58	3.30	7.19	3.94	21.61	115.92
		171.58	311.30	157.19	603.94	421.61	618.61
9	Net Profit / (Loss) for the Period (9-10)	429.78	980.36	356.96	1,693.92	921.46	1,316.83
10	Other Comprehensive Income (OCI):						
	Items that will not be reclassified to profit or Loss:	(2.65)	(2.41)	(6.81)	(9.44)	(20.43)	(12.35)
	Income Tax effect on the above	(1.09)	(0.99)	(1.98)	(3.06)	(5.95)	(3.60)
		(1.56)	(1.42)	(4.83)	(6.38)	(14.48)	(8.75)
11	Total Comprehensive Income for the period (11+12)	428.22	978.94	352.13	1,687.53	906.98	1,308.08
12	Earning Per Equity Share of Rs.10/- each (Refer Note No.3)	14.22	32.43	11.81	56.03	30.48	43.56
	Basic / Diluted (not annualised)						
	Paid-up equity share capital (Face Value of Rs.10/- each)	302.33	302.33	302.33	302.33	302.33	302.33
13	Reserves excluding Revaluation Reserve						12,331.32
	as per balance sheet of previous accounting year						



Notes:

The above standalone Financial Results have been reviewed and recommended by the Audit Committee on 11th February, 2022 and have been approved by the Board of Directors at its meeting held on 11th February, 2022. The statutory auditors of the Company have carried out a limited review of Standalone financial results for the quarter and nine months ended 31st December, 2021 and expressed an unmodified conclusion thereon.

The standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

For Quarter ending 30.09.2021 and for the nine months period ending 31.12.2021, Exceptional Item of Rs.777.25 Lakhs represents Profit on sale of non revenue generating Land and Buildings which resulted in substantial enhancement in EPS. Hence EPS for the previous quarter and corresponding nine months period ending 31st December, 2021 are not comparable.

In pursuance of share purchase agreement executed on 13.12.2021 with Chemwerth Inc, the Company has received an amount of Rs.7,45,73,258/- towards sale consideration of 10% its stake in M/s. Mahi drugs Private Limited (Wholly owned Subsidiary) i.e 4,71,510 Shares @ Rs.159/- per share. Balance consideration of Rs.3,96,832/- was received in second week of January, 2022 and transfer of said shares is under process.

The Company is engaged in manufacturing of Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108.

Figures for the previous period have been reclassified/ regrouped wherever necessary to conform to current period's classification.

For SMS Lifesciences India Limited



TVVSN Murthy
Managing Director
DIN: 00465198

Place: Hyderabad
Date : 11-02-2022

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

**Review Report to
The Board of Directors
SMS Lifesciences India Limited**

We have reviewed the accompanying statement of unaudited standalone financial results of SMS Lifesciences India Limited ("the Company"), for the quarter ended 31st December 2021 ("the statement"), attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (the "Listing Regulations").

This statement which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 (Ind AS 34) "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express conclusion on the Statements based on our review.


We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by Independent Auditor of Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statements is free of material misstatement. A review of the interim financial information consists of making inquires primarily of company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ("Ind AS") specified under Section 133 of Companies Act, 2013 as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad
Date: 11.02.2022

UDIN: 22026548ABIRRY1999

For Rambabu & Co.,
Chartered Accountants
Reg. No.0029765


G.V.L. Prasad
Partner
M. No. 026548



SMS LIFESCIENCES INDIA LIMITED

(CIN: L74930TG2006PLC050223)


Regd. Office: Plot No.19-III, Opp. BVBP School, Road No.71, Jubilee Hills, Hyderabad - 500 096

Tel:+91-40-6628 8888, Fax:91-40-2355 1401, Email: info@smslife.in

Consolidated Statement of Un-Audited Financial Results for the Quarter and Nine Months Ended 31st December, 2021

(Rs. In Lakhs)

S.No	Particulars	Quarter Ended			Nine Months Ended		Year ended
		31.12.2021	30.09.2021	31.12.2020	31.12.2021	31.12.2020	31.03.2021
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue From Operations	9,105.91	8,675.12	6,656.90	25,408.02	18,307.80	26,559.18
2	Other Income	3.48	66.92	61.33	35.22	75.49	178.10
3	Total Revenue	9,109.39	8,742.04	6,718.23	25,443.24	18,383.29	26,737.28
4	Expenses						
	(a) Cost of Materials Consumed	5,579.73	5,810.14	3,529.07	15,347.77	9,008.40	13,516.65
	(b) Changes in Inventories	(623.90)	(1,282.20)	(61.28)	(1,656.34)	509.21	187.20
	(c) Manufacturing Expenses	1,797.84	1,736.97	1,438.09	4,917.52	3,465.62	5,020.67
	(d) Employee Benefits Expense	1,086.29	966.64	788.85	2,934.23	2,205.93	3,065.81
	(e) Finance Cost	148.92	181.64	106.74	442.42	354.13	452.93
	(f) Depreciation and Amortization Expense	261.35	268.91	196.74	742.94	588.71	786.16
	(g) Other Expenses	419.97	482.57	293.41	1,195.21	968.72	1,751.11
	Total Expenses - (a to g)	8,670.20	8,164.67	6,291.62	23,923.75	17,100.72	24,780.53
5	Profit Before Exceptional and Extraordinary Items and Tax (3-4)	439.19	577.37	426.61	1,519.49	1,282.57	1,956.75
6	Exceptional / Extraordinary Items	-	777.25	-	777.25	-	-
7	Profit Before Tax (5+6)	439.19	1,354.62	426.61	2,296.74	1,282.57	1,956.75
8	Tax Expenses						
	(1) Current Tax	170.00	288.00	150.00	600.00	411.00	526.50
	(2) Relating to Earlier Year	-	-	-	-	-	(38.93)
	(2) Deferred Tax	36.28	41.37	7.07	75.82	21.27	113.52
		206.28	329.37	157.07	675.82	432.27	601.09
9	Net Profit / (Loss) for the Period (7-8)	232.91	1,025.25	269.54	1,620.92	850.30	1,355.66
10	Other Comprehensive Income/(Loss) (OCI):						
	(A) Items that will not be reclassified to statement of Profit & Loss						
	Remeasurement of post-employment benefit obligations	(2.00)	(1.82)	(6.43)	(7.66)	(19.20)	(10.39)
11	Income Tax effect on the above	(0.91)	(0.82)	(1.88)	(2.57)	(5.61)	(3.05)
12	Other Comprehensive Income/(Loss) after tax for the Period / Year (13-14)	(1.09)	(1.00)	(4.55)	(5.09)	(13.59)	(7.34)
13	Total comprehensive Income for the period/year (14+18)	231.82	1,024.25	264.99	1,615.83	836.71	1,348.32
14	Earning Per Equity Share of Rs.10/- each						
	Basic / Diluted (not annualised) (Refer Note No.4)	7.70	33.91	8.92	53.61	28.13	44.84
15	Paid-up equity share capital (Face Value of Rs.10/- each)	302.33	302.33	302.33	302.33	302.33	302.33
16	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year						12,619.29




Notes:

- 1 The above consolidated Financial Results have been reviewed and recommended by the Audit Committee on 11th February, 2022 and have been approved by the Board of Directors at its meeting held on 11th February, 2022. The statutory auditors of the Company have carried out a limited review of Consolidated financial results for the quarter and nine months ended 31st December, 2021 and expressed an unmodified conclusion thereon.
- 2 The consolidated financial results of the Company have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- 3 The Consolidated financial results include the financial results of Mahi Drugs Private Limited a wholly owned subsidiary and are prepared by applying Ind AS 110- "Consolidated Financial Statements".
- 4 For Quarter ending 30.09.2021 and for the nine months period ending 31.12.2021, Exceptional Item of Rs.777.25 Lakhs represents Profit on sale of non revenue generating Land and Buildings which resulted in substantial enhancement in EPS. Hence EPS for the previous quarter and corresponding nine months period ending 31st December, 2021 are not comparable.
- 5 In pursuance of share purchase agreement executed on 13.12.2021 with Chemwerth Inc, the Company has received an amount of Rs.7,45,73,258/- towards sale consideration of 10% its stake in M/s. Mahi drugs Private Limited (Wholly owned Subsidiary) i.e 4,71,510 Shares @ Rs.159/- per share. Balance consideration of Rs.3,96,832/- was received in second week of January, 2022 and transfer of said shares is under process.
- 6 The Consolidated entity is engaged in manufacturing Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108.
- 7 Figures for the previous period have been reclassified / regrouped wherever necessary to conform to current period's classification.

Place: Hyderabad
Date : 11-02-2022

For SMS Lifesciences India Limited


TVVSN Murthy
Managing Director
DIN : 00465198

Independent Auditor's Review Report on review of Interim Consolidated Financial Results

To the Board of Directors of
SMS Lifesciences India Limited

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial results of **SMS Lifesciences India Limited** ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group") for the quarter ended 31st December, 2021 (the "statement"), being submitted by the parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This statement is the responsibility of the Parent's Management and has been approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting (Ind AS 34)", prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim Financial information performed by the Independent Auditor of the Entity*, issued by Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the result of the following entities

- a. SMS Lifesciences India Limited
- b. M/s. Mahi Drugs Private Limited (wholly owned subsidiary)



5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The consolidated unaudited financial results includes the interim financial statements/ financial information of above subsidiary, whose interim financial statements / financial information reflect total revenue of Rs.732.07 lakhs, total loss of Rs. 168.07 lakhs and total comprehensive loss of Rs.167.60 lakhs for the Quarter ended 31st December, 2021, as considered in the Statement. According to the information and explanations given to us by the Management, the interim financial statements / financial information is not material to the Group. Our conclusion on the Statement is not modified in respect of our reliance on the interim financial statements / financial information certified by the Management.

Place: Hyderabad


Date: 11.02.2022

UDIN: 22026548ABISEY8321

For Rambabu & Co.,

Chartered Accountants

Reg. No.0029765



GVL Prasad

Partner

M. No. 026548

